Danaher Q3 2026 Earnings: The $6.6B Quarter That Masimo Built

On October 21, 2026, Danaher Corporation reported third-quarter revenue of $6,554 million, up 8.5% as reported, alongside net earnings of $1,235 million and adjusted diluted EPS of $2.11 (+11.5% as reported). It was the first quarter under new CEO Julie Sawyer Montgomery, the first full quarter owning Masimo — the $9.8 billion patient-monitoring acquisition that closed in June — and a quarter in which the tax line printed a $75 million benefit instead of an expense. Growth is accelerating, the balance sheet is levering up to pay for it, and more than a fifth of reported earnings came from a tax settlement. That is the mix to untangle.

The Headline Numbers​

Danaher's fiscal year is the calendar year; Q3 2026 ended September 25, 2026 (Danaher quarters close on the last Friday). Every figure below comes from the Form 10-Q and the earnings release (Exhibit 99.1 to the same-day Form 8-K), whose income statements agree line for line. One auditor's note before the table: the release's growth percentages run about two-tenths of a point hotter than its own printed figures divide to (8.5% vs. 8.3% for the quarter, 6.0% vs. 5.9% for nine months) — beyond what rounding of the published millions can explain. The tables below use the filed figures and the growth rates they compute to.

Read the table in two halves and the quarter splits open. Above the operating line it is a genuinely good quarter: revenue up 8.3%, gross margin expanding, operating profit up 7.9%. Below it, the 36.0% net-income growth is flattered twice over — first by a $263 million discrete tax benefit (the release of uncertain-tax-position reserves on audit settlements, Note 7 of the 10-Q), which flipped the tax line from a $168 million provision a year ago to a $75 million benefit, and second by a $28 million discontinued-operations benefit of the same nature. Strip both and net earnings grew 4.0%, not 36.0%. The release's own "up 34.5%" attaches to diluted EPS ($1.71 vs. $1.27), not to net earnings. Cash flow, immune to both flatteries, still grew double digits — operating cash up 13.5%, free cash flow up 19.1% — which is the number that says the operating story is real.

Revenue Deep Dive​

Three segments, three different quarters — and the headline growth was overwhelmingly bought. Acquisitions contributed 6.5 of the 8.5 reported points of growth, all of it Masimo inside Diagnostics.

Diagnostics is the company now — 44% of revenue — and its 17.0% print is the Masimo quarter. Closed June 10 for approximately $9.8 billion ($180.00 per share), Masimo's monitoring technologies contributed roughly $400 million of sales in their first full quarter by the release's own 16.5-point acquisition bridge, annualizing near the $1.5 billion Masimo generated in 2025. But note what the segment table confesses: Diagnostics operating profit fell 7.7% ($665 million to $614 million) while sales grew 17%. The culprits are all Masimo-shaped — segment amortization more than doubling from $48 million to $133 million, $84 million of acquisition-related inventory step-up flowing through cost of sales, and a respiratory-testing headwind (sales down to roughly $350 million from $500 million a year ago) dragging 2.5 points off company core growth. Excluding respiratory, Diagnostics core growth was 7.0% and the company print was 5.5%.

Biotechnology looks flat and isn't. Reported growth of 0.5% buries 5.0% core growth, with 4.0 points shaved off by a new disclosure: tariff refunds returned to customers, which Danaher began excluding from core growth this quarter. More striking is the profit line — operating profit up 35.5% with margin leaping from 19.6% to 26.4%. Part of that is an easier impairment comparison ($52 million of facility charges this year vs. $86 million last year), but even adding impairments back, the segment grew operating profit over 20% on flat reported sales. Bioprocessing demand is recovering and the cost base has been reset. This is the quarter's quietest beat and arguably its best.

Life Sciences grew 4.1% reported and 4.5% core, with operating profit up 16.7% and margin ticking up to 13.9%. Steady share-gain business at the lowest margin of the three — the segment the new CEO's "defining leader in Life Sciences and Diagnostics" framing implicitly promises to fix or outgrow. Unallocated corporate and other costs of $105 million bridge the three segments' combined $1,350 million of operating profit to the reported $1,245 million.

On the management-signal scan, this release talks demand and execution, not cycles or pricing. CEO Julie Sawyer Montgomery — appointed August 3, in the chair since October 1, in her first earnings call — said the company was "encouraged by the improving trends we saw across our end markets" and credited "DBS-driven execution" for converting "improving demand into strong financial performance." That is a robust-demand signal in plain words, and the balance sheet backs it: trade receivables are up just 5.4% since New Year even as the quarterly sales run-rate accelerated, so revenue is not being pulled forward on credit. What is absent matters too. There is no "demand exceeds supply," no upcycle language, no pricing-momentum wording and no tight-supply commentary anywhere in the release. For a franchise growing core revenue 5.5% ex-respiratory, the absence of pricing language reads as volume-led growth — consistent with gross margin expanding only 0.3 points.

The Margin Story​

Margins across five checkpoints tell a story of a trough left behind, with one asterisk the size of the tax line:

Gross margin is the metronome — 58–60% in every period shown — and the 0.3-point quarterly expansion came mechanically from Biotechnology leverage and Life Sciences mix, partly offset by the $84 million Masimo inventory step-up sitting in cost of sales. Operating margin is flat at 19.0% because SG&A grew 8.4%, a touch faster than revenue, as Masimo's commercial organization consolidated in. Neither line is where the action is.

The action is the net margin jumping from 15.0% to 18.8% while operating margin stood still. Mechanically that is the tax benefit plus lower below-the-line drag: other expense shrank to $9 million, and interest income of $31 million (vs. $3 million) absorbed part of the doubled interest expense. The ex-one-offs row restores the real trend — 14.4%, slightly below last year's 15.0%, because interest expense doubled to $135 million on the Masimo debt while the acquired earnings are still burdened by amortization. That cross — rising interest against not-yet-earning acquisition assets — is the margin story to watch for the next four quarters. A corroborating detail for the tax split: the implied ordinary provision of $188 million is a 16.6% rate on pre-tax earnings, landing almost exactly on management's ~17% forward effective-rate guide. The quarter's tax math ties.

The One Big Question: What Did $9.8 Billion Actually Buy?​

Masimo is the largest Danaher deal in years and the entire quarter orbits it, so judge it on three falsifiable lines: growth contribution, margin dilution, and balance-sheet cost.

Growth contribution: confirmed, roughly as advertised. Masimo's ~$400 million quarter annualizes to the $1.5 billion 2025 revenue Danaher disclosed, implying a ~6.5x sales multiple — full but not absurd for a strategic monitoring franchise. Without it, company growth would have been roughly 2% instead of 8.5%.

Margin dilution: real and front-loaded. Diagnostics segment margin compressed 5.7 points (27.0% to 21.3%) under $85 million of incremental amortization and the $84 million inventory step-up. The step-up burns off; the amortization ($513 million company-wide this quarter, up from $433 million) does not. This is why GAAP diluted EPS of $1.71 and adjusted EPS of $2.11 now live on different planets — the bridge is worth printing in full:

Two things stand out. First, amortization alone is 43% of GAAP EPS — the permanent purchase-accounting toll of the Danaher model, now permanently higher with $5.0 billion of fresh Masimo intangibles. Second, the $0.37 discrete-tax add-back means management's own adjusted number agrees the tax benefit is not operating earnings. Bulls and bears should both start from the same place: GAAP $1.71 includes $0.37 of tax benefit, so operating GAAP is ~$1.34, while adjusted $2.11 excludes both the benefit and the amortization.

Balance-sheet cost: $8.1 billion of incremental debt. Long-term debt rose to $24,388 million from $18,416 million at New Year, and notes payable jumped from $2 million to $2,094 million on commercial paper — together funding the $9,881 million of nine-month acquisition cash against $4,742 million of operating cash flow. Interest expense doubled year over year and will stay there: Q4 guidance assumes ~$120 million of net interest. The offsets are that buybacks slowed to $894 million (from $3,088 million) rather than stopping, the dividend grew to $790 million, and cash still ended higher at $5,682 million. Leverage up, capital returns intact, coverage comfortable — the standard Danaher acquisition financing, executed cleanly.

The forward checkpoints are dated. Q4 guidance calls for 4–5% core growth ex-respiratory with respiratory a ~150-basis-point headwind, and full-year adjusted EPS was raised to $8.57–$8.62 from $8.45–$8.60 — implying a Q4 adjusted print of roughly $2.46–$2.51 against $6.11 banked in nine months. Watch Diagnostics margin for the step-up burn-off, and watch whether Biotech's 5% core growth sustains into a second half of recovery.

Tracking a $93B Balance Sheet in Plain Text​

A serial acquirer's accounts are where purchase accounting goes to blur — goodwill stacking, amortization dragging, step-ups flowing through cost of sales — and double-entry bookkeeping forces every dollar of it to reconcile. That is why this ledger exists, and how we model every company documents the conventions. The ledger opens at FY2024 — two audited 10-K annuals plus the current quarter, the convention for bootstrapping a ledger mid-year — and every figure below ties to the filings named in each period file's source banner.

Here is the quarter's income statement exactly as the ledger records it — income negative, expenses positive, summing to zero, with the tax one-off split into labeled postings:

; FY2026Q3 Income Statement — quarter ended September 25, 2026
; Check: −6,554 + 2,717 + 2,159 + 433 + 9 + 135 − 31 + 188 − 263 − 28 + 1,235 = 0 ✓
 
2026-09-25 * "Danaher Corporation" "FY2026Q3 Income Statement"
  Income:Revenue                         -6554 MUSD  ; sales
  Expenses:CostOfRevenue                   2717 MUSD  ; cost of sales
  Expenses:SellingGeneralAdministrative     2159 MUSD  ; selling, general and administrative expenses
  Expenses:ResearchAndDevelopment            433 MUSD  ; research and development expenses
  Expenses:OtherNet                            9 MUSD  ; other expense, net
  Expenses:Interest                          135 MUSD  ; interest expense
  Expenses:Interest                          -31 MUSD  ; interest income
  Expenses:IncomeTax                         188 MUSD  ; ordinary provision (263 discrete benefit less 75 net benefit; see banner)
  Expenses:IncomeTax                        -263 MUSD  ; Note 7: net discrete tax benefits, release of uncertain-tax-position reserves from audit settlements
  Expenses:DiscontinuedOperations            -28 MUSD  ; Note 3: $28 tax benefit from release of reserves on joint Veralto/Fortive returns (audit settlements)
  Equity:Adjustments                        1235 MUSD  ; net earnings offset (RE set by balance assertion)

The balance-sheet number that tells the quarter's story is goodwill: $43,151 million at New Year to $47,315 million nine months later, the $4,876 million Masimo premium landing alongside $5,006 million of fresh intangibles — while long-term debt plus notes payable rose to $26,482 million to fund it. That pair of lines is the entire 2026 capital story: nearly $10 billion of patient-monitoring assets bought with operating cash plus fresh debt, with buybacks and a growing dividend still running on top. Watch those two lines next quarter; everything else is commentary.

The Multi-Year Arc​

Five checkpoints from the post-COVID unwind through the Masimo quarter — with goodwill as the shadow P&L of the acquisition machine:

The arc is a U with an expensive right wall. Revenue fell from $26.6 billion to a $23.9 billion plateau as pandemic-era bioprocessing demand unwound, operating margin compressed nine points from its 28.3% peak, and growth resumed in FY2025 (+2.9%) before accelerating to 8.3% this quarter. Through the whole trough Danaher never stopped buying: goodwill bottomed at $40.5 billion and has risen every year-end since, now $47.3 billion with Masimo the largest addition. Net income is still 40% below its FY2022 peak on a trailing basis ($4.3 billion vs. $7.2 billion) despite revenue nearly recovering, because amortization, interest and (ex-one-off) taxes each take a larger bite than they did — and because the FY2022–23 figures carry large discontinued-operations contributions from businesses since separated. That is the compounding bargain in one table: shareholders fund perpetual acquisitions through prodigious free cash flow (nearly $4.0 billion in nine months), diluted shares fall every year (706.8 million vs. 713.7 million), and in exchange growth never depends on any single product cycle. It works until one big deal doesn't — and Masimo, at nearly 10% of the balance sheet, is now the deal that has to work.

The Verdict: Bull vs. Bear​

Bull Case

• Core revenue growth ex-respiratory accelerated to 5.5%, up from 4.5% last quarter and 2.5% a year ago — with Q4 guided at 4–5%.
• Biotechnology is fixed: 5.0% core growth with operating margin back above 26%, growing profit 20%+ ex-impairments on flat reported sales.
• Masimo is performing to script at ~$400 million a quarter, and the Diagnostics margin compression is identifiable purchase accounting ($84 million step-up, $85 million incremental amortization), not share loss.
• Free cash flow grew 19.1% with a 1.35x conversion ratio on (flattered) net earnings — 1.7x on ex-one-off earnings — funding $894 million of buybacks and a growing dividend even in a $9.8 billion deal year.
• A new CEO with a diagnostics pedigree (ex-Beckman Coulter chief) and an explicit share-gain mandate arrives with the balance sheet still flexible: $5.7 billion of cash, investment-grade leverage.

Bear Case

• The 36.0% earnings growth is a tax artifact: ex-one-offs, net earnings grew 4.0% — and the "improving demand" management cites has not yet shown up in pricing power, with no pricing language anywhere in the release.
• Interest expense doubled to $135 million and stays there ($120 million guided quarterly net), while $5.0 billion of Masimo intangibles permanently raise the amortization toll — GAAP EPS will trail adjusted by 30–40% indefinitely.
• Diagnostics, now 44% of revenue, earns a 21.3% margin, down 5.7 points year over year; if Masimo integration stumbles, there is no larger segment left to offset it.
• Respiratory testing (~$350 million vs. ~$500 million) remains a 2.5-point drag, with seasonally-strong Q4 guided at only ~$400 million against ~$500 million a year ago — and Life Sciences' 13.9% margin is still the weakest link the "defining leader" ambition has to answer for.
• Goodwill is now 51% of total assets ($47.3 billion of $93.3 billion) — the balance sheet has less room for the next $10 billion deal without an equity raise or a leverage covenant conversation.

Our Take

Buy the execution, discount the headline. The operating quarter — 5.5% core growth ex-respiratory, a fixed Biotechnology franchise, 19% free-cash-flow growth — is genuinely the best Danaher has printed since the unwind ended, and Masimo's first full quarter lands squarely in the "performing to script" zone with identified, burning-off margin drag. But $291 million of the $1,235 million in net earnings is tax settlements that will not repeat, the release's percentages flatter the printed figures by two-tenths, and the balance sheet just absorbed its largest deal in years at 6.5x sales. At ~$1.34 of operating GAAP EPS and $2.11 adjusted, you are paying a full multiple for the franchise and getting the acquisition optionality for something close to free — which is exactly when Danaher has historically been worth owning, provided Masimo's next three quarters look like this one. Watch Diagnostics margin and Biotech core growth; everything else is commentary.